99 results
8-K
EX-10.10
COCP
Cocrystal Pharma Inc
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
by the Board from time to time.
6. EMPLOYEE BENEFIT PROGRAMS.
(a) General Benefits. During the Term, Executive shall be entitled to participate … .
(a) The Annual Bonus, and any and all stock based compensation (such as options and equity awards) (collectively, the “Clawback Benefits”) shall be subject
8-K
EX-10.8
COCP
Cocrystal Pharma Inc
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
to time.
6. EMPLOYEE BENEFIT PROGRAMS.
(a) General Benefits. During the Term, Executive shall be entitled to participate in such employee benefit … and all stock based compensation (such as options and equity awards) (collectively, the “Clawback Benefits”) shall be subject to “Company Clawback Rights
8-K
EX-10.9
COCP
Cocrystal Pharma Inc
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
.
(a) General Benefits. During the Term, Executive shall be entitled to participate in such employee benefit plans and programs of BioZone as are made available … and equity awards) (collectively, the “Clawback Benefits”) shall be subject to “Company Clawback Rights” as follows: During the period that Executive
8-K
EX-10.2
COCP
Cocrystal Pharma Inc
8 Jan 14
Completion of Acquisition or Disposition of Assets
12:00am
with certain compensation and benefits in return for such employment services; and
WHEREAS, the Executive wishes to be employed by the Company and to provide … employment services to the Company in return for certain compensation and benefits;
NOW THEREFORE, in consideration of the foregoing, of the mutual
8-K
EX-10.1
COCP
Cocrystal Pharma Inc
8 Jan 14
Completion of Acquisition or Disposition of Assets
12:00am
with certain compensation and benefits in return for such employment services; and
WHEREAS, the Executive wishes to be employed by the Company … and to provide employment services to the Company in return for certain compensation and benefits;
NOW THEREFORE, in consideration of the foregoing
10-K/A
ehvc umbwqr
13 Sep 13
Annual report (amended)
12:00am
8-K
EX-2.1
rs3nzzw25l
1 Dec 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
servmjz17 nw57
8 Jan 14
Completion of Acquisition or Disposition of Assets
12:00am
8-K
sl7vh
27 Feb 15
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
ju9 sbj3l
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
mli350k fuyhhgq
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
S-8
EX-10.1
ufuw9cpcz
11 May 18
Registration of securities for employees
4:16pm
8-K
EX-99.1
wdscq5r0q7o7b
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-99.1
kguynlao
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm